Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 324 of 324 entries
Sorted by: Best Match Show Resources per page
Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study.

Journal of pharmaceutical and biomedical analysis

Reeder JA, Abdallah IA, Bach T, O'Sullivan CT, Xu Y, Nalbant D, An G.
PMID: 34979494
J Pharm Biomed Anal. 2021 Dec 06;210:114521. doi: 10.1016/j.jpba.2021.114521. Epub 2021 Dec 06.

Cefazolin is widely used during surgery to prevent surgical site infections (SSIs). Although cefazolin redosing is often needed due to its short half-life, the appropriate redosing schedule remains controversial and there is limited information on cefazolin disposition following repeated...

Cite
Reeder JA, Abdallah IA, Bach T, et al. Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2021;210:114521doi: 10.1016/j.jpba.2021.114521.
Reeder, J. A., Abdallah, I. A., Bach, T., O'Sullivan, C. T., Xu, Y., Nalbant, D., & An, G. (2021). Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 210114521. https://doi.org/10.1016/j.jpba.2021.114521
Reeder, Joshua A, et al. "Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study." Journal of pharmaceutical and biomedical analysis vol. 210 (2021): 114521. doi: https://doi.org/10.1016/j.jpba.2021.114521
Reeder JA, Abdallah IA, Bach T, O'Sullivan CT, Xu Y, Nalbant D, An G. Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2021 Dec 06;210:114521. doi: 10.1016/j.jpba.2021.114521. Epub 2021 Dec 06. PMID: 34979494.
Copy Download .nbib Format: NLM
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection.

Virus evolution

Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M.
PMID: 34532060
Virus Evol. 2021 Jul 09;7(2):veab057. doi: 10.1093/ve/veab057. eCollection 2021.

The scale of the HIV-1 epidemic underscores the need for a vaccine. The multitude of circulating HIV-1 strains together with HIV-1's high evolvability hints that HIV-1 could adapt to a future vaccine. Here, we wanted to investigate the effect...

Cite
Lewitus E, Sanders-Buell E, Bose M, et al. RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evol. 2021;7(2):veab057doi: 10.1093/ve/veab057.
Lewitus, E., Sanders-Buell, E., Bose, M., O'Sullivan, A. M., Poltavee, K., Li, Y., Bai, H., Mdluli, T., Donofrio, G., Slike, B., Zhao, H., Wong, K., Chen, L., Miller, S., Lee, J., Ahani, B., Lepore, S., Muhammad, S., Grande, R., Tran, U., Dussupt, V., Mendez-Rivera, L., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Rerks-Ngarm, S., O'Connell, R. J., Janes, H., Gilbert, P. B., Gramzinski, R., Vasan, S., Robb, M. L., Michael, N. L., Krebs, S. J., Herbeck, J. T., Edlefsen, P. T., Mullins, J. I., Kim, J. H., Tovanabutra, S., & Rolland, M. (2021). RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus evolution, 7(2), veab057. https://doi.org/10.1093/ve/veab057
Lewitus, Eric, et al. "RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection." Virus evolution vol. 7,2 (2021): veab057. doi: https://doi.org/10.1093/ve/veab057
Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M. RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evol. 2021 Jul 09;7(2):veab057. doi: 10.1093/ve/veab057. eCollection 2021. PMID: 34532060; PMCID: PMC8438874.
Copy Download .nbib Format: NLM
Online dental trauma course for medical education.

Dental traumatology : official publication of International Association for Dental Traumatology

Yeng T, O'Sullivan AJ, Shulruf B.
PMID: 34148285
Dent Traumatol. 2021 Dec;37(6):803-806. doi: 10.1111/edt.12696. Epub 2021 Jun 20.

A literature review identified a knowledge deficit among medical doctors about dental trauma management. To overcome this knowledge gap, a proposal to integrate dental traumatology teaching into the medical curriculum was made to raise medical students' awareness of, and...

Cite
Yeng T, O'Sullivan AJ, Shulruf B. Online dental trauma course for medical education. Dent Traumatol. 2021;37(6):803-806doi: 10.1111/edt.12696.
Yeng, T., O'Sullivan, A. J., & Shulruf, B. (2021). Online dental trauma course for medical education. Dental traumatology : official publication of International Association for Dental Traumatology, 37(6), 803-806. https://doi.org/10.1111/edt.12696
Yeng, Thai, et al. "Online dental trauma course for medical education." Dental traumatology : official publication of International Association for Dental Traumatology vol. 37,6 (2021): 803-806. doi: https://doi.org/10.1111/edt.12696
Yeng T, O'Sullivan AJ, Shulruf B. Online dental trauma course for medical education. Dent Traumatol. 2021 Dec;37(6):803-806. doi: 10.1111/edt.12696. Epub 2021 Jun 20. PMID: 34148285.
Copy Download .nbib Format: NLM
Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in .

ACS sensors

Ortiz M, Jauset-Rubio M, Skouridou V, Machado D, Viveiros M, Clark TG, Simonova A, Kodr D, Hocek M, O'Sullivan CK.
PMID: 34797987
ACS Sens. 2021 Nov 19; doi: 10.1021/acssensors.1c01710. Epub 2021 Nov 19.

Here, we report the electrochemical detection of single-point mutations using solid-phase isothermal primer elongation with redox-labeled oligonucleotides. A single-base mutation associated with resistance to rifampicin, an antibiotic commonly used for the treatment of

Cite
Ortiz M, Jauset-Rubio M, Skouridou V, et al. Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in . ACS Sens. 2021;doi: 10.1021/acssensors.1c01710.
Ortiz, M., Jauset-Rubio, M., Skouridou, V., Machado, D., Viveiros, M., Clark, T. G., Simonova, A., Kodr, D., Hocek, M., & O'Sullivan, C. K. (2021). Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in . ACS sensors, . https://doi.org/10.1021/acssensors.1c01710
Ortiz, Mayreli, et al. "Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in ." ACS sensors vol. (2021). doi: https://doi.org/10.1021/acssensors.1c01710
Ortiz M, Jauset-Rubio M, Skouridou V, Machado D, Viveiros M, Clark TG, Simonova A, Kodr D, Hocek M, O'Sullivan CK. Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in . ACS Sens. 2021 Nov 19; doi: 10.1021/acssensors.1c01710. Epub 2021 Nov 19. PMID: 34797987.
Copy Download .nbib Format: NLM
Spectroscopic evaluation of U.

Journal of synchrotron radiation

Yorkshire AS, Stennett MC, Walkley B, O'Sullivan SE, Mottram LM, Bailey DJ, Provis JL, Hyatt NC, Corkhill CL.
PMID: 34985426
J Synchrotron Radiat. 2022 Jan 01;29:89-102. doi: 10.1107/S1600577521011553. Epub 2022 Jan 01.

Portland cement based grouts used for radioactive waste immobilization contain high replacement levels of supplementary cementitious materials, including blast-furnace slag and fly ash. The minerals formed upon hydration of these cements may have capacity for binding actinide elements present...

Cite
Yorkshire AS, Stennett MC, Walkley B, et al. Spectroscopic evaluation of U. J Synchrotron Radiat. 2022;29:89-102doi: 10.1107/S1600577521011553.
Yorkshire, A. S., Stennett, M. C., Walkley, B., O'Sullivan, S. E., Mottram, L. M., Bailey, D. J., Provis, J. L., Hyatt, N. C., & Corkhill, C. L. (2022). Spectroscopic evaluation of U. Journal of synchrotron radiation, 2989-102. https://doi.org/10.1107/S1600577521011553
Yorkshire, Antonia S, et al. "Spectroscopic evaluation of U." Journal of synchrotron radiation vol. 29 (2022): 89-102. doi: https://doi.org/10.1107/S1600577521011553
Yorkshire AS, Stennett MC, Walkley B, O'Sullivan SE, Mottram LM, Bailey DJ, Provis JL, Hyatt NC, Corkhill CL. Spectroscopic evaluation of U. J Synchrotron Radiat. 2022 Jan 01;29:89-102. doi: 10.1107/S1600577521011553. Epub 2022 Jan 01. PMID: 34985426.
Copy Download .nbib Format: NLM
Physiological response of weaned piglets to two transport durations observed in a Canadian commercial setting.

Journal of animal science

Golightly HR, Brown J, Bergeron R, Poljak Z, Roy RC, Seddon YM, O'Sullivan TL.
PMID: 34695200
J Anim Sci. 2021 Dec 01;99(12). doi: 10.1093/jas/skab311.

Observational studies describing the impact of transport duration on weaned piglet welfare are limited. Current Canadian transport regulations are heavily informed by studies involving market hogs. Due to physiological differences between weaned piglets and market hogs, additional data on...

Cite
Golightly HR, Brown J, Bergeron R, et al. Physiological response of weaned piglets to two transport durations observed in a Canadian commercial setting. J Anim Sci. 2021;99(12)doi: 10.1093/jas/skab311.
Golightly, H. R., Brown, J., Bergeron, R., Poljak, Z., Roy, R. C., Seddon, Y. M., & O'Sullivan, T. L. (2021). Physiological response of weaned piglets to two transport durations observed in a Canadian commercial setting. Journal of animal science, 99(12), . https://doi.org/10.1093/jas/skab311
Golightly, Hannah R, et al. "Physiological response of weaned piglets to two transport durations observed in a Canadian commercial setting." Journal of animal science vol. 99,12 (2021). doi: https://doi.org/10.1093/jas/skab311
Golightly HR, Brown J, Bergeron R, Poljak Z, Roy RC, Seddon YM, O'Sullivan TL. Physiological response of weaned piglets to two transport durations observed in a Canadian commercial setting. J Anim Sci. 2021 Dec 01;99(12). doi: 10.1093/jas/skab311. PMID: 34695200; PMCID: PMC8653940.
Copy Download .nbib Format: NLM
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom.

JAMA network open

Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, Jacob A, Blain C, Halfpenny C, Hemingway C, O'Sullivan E, Hobart J, Fisniku LK, Martin R, Dopson R, Cooper SA, Williams V, Waters PJ, Ramdas S, Leite MI, Palace J.
PMID: 35006246
JAMA Netw Open. 2022 Jan 04;5(1):e2142780. doi: 10.1001/jamanetworkopen.2021.42780.

IMPORTANCE: Longer-term outcomes and risk factors associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not well established.OBJECTIVE: To investigate longer-term risk of relapse and factors associated with this risk among patients with MOGAD.DESIGN, SETTING, AND PARTICIPANTS: This large,...

Cite
Satukijchai C, Mariano R, Messina S, et al. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom. JAMA Netw Open. 2022;5(1):e2142780doi: 10.1001/jamanetworkopen.2021.42780.
Satukijchai, C., Mariano, R., Messina, S., Sa, M., Woodhall, M. R., Robertson, N. P., Ming, L., Wassmer, E., Kneen, R., Huda, S., Jacob, A., Blain, C., Halfpenny, C., Hemingway, C., O'Sullivan, E., Hobart, J., Fisniku, L. K., Martin, R., Dopson, R., Cooper, S. A., Williams, V., Waters, P. J., Ramdas, S., Leite, M. I., & Palace, J. (2022). Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom. JAMA network open, 5(1), e2142780. https://doi.org/10.1001/jamanetworkopen.2021.42780
Satukijchai, Chanjira, et al. "Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom." JAMA network open vol. 5,1 (2022): e2142780. doi: https://doi.org/10.1001/jamanetworkopen.2021.42780
Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, Jacob A, Blain C, Halfpenny C, Hemingway C, O'Sullivan E, Hobart J, Fisniku LK, Martin R, Dopson R, Cooper SA, Williams V, Waters PJ, Ramdas S, Leite MI, Palace J. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom. JAMA Netw Open. 2022 Jan 04;5(1):e2142780. doi: 10.1001/jamanetworkopen.2021.42780. PMID: 35006246.
Copy Download .nbib Format: NLM
Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection.

Open forum infectious diseases

Song H, Bose M, Pinyakorn S, Sanders-Buell E, O'Sullivan AM, Silas D, Trichavaroj R, Nuntapinit B, Pham PT, Akapirat S, Kroon E, de Souza M, Gramzinski R, Michael NL, Robb ML, Vasan S, Tovanabutra S, Ananworanich J.
PMID: 33748316
Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa429. doi: 10.1093/ofid/ofaa429. eCollection 2020 Oct.

We analyzed human immunodeficiency virus envelope diversity in 98 acute infections. The within-host genetic diversity, divergence from transmitted/founder (T/F) strain, and the observed frequency of multiple T/F infections increased with Fiebig stage. These data identify rapid viral dynamics during...

Cite
Song H, Bose M, Pinyakorn S, et al. Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. Open Forum Infect Dis. 2020;7(10):ofaa429doi: 10.1093/ofid/ofaa429.
Song, H., Bose, M., Pinyakorn, S., Sanders-Buell, E., O'Sullivan, A. M., Silas, D., Trichavaroj, R., Nuntapinit, B., Pham, P. T., Akapirat, S., Kroon, E., de Souza, M., Gramzinski, R., Michael, N. L., Robb, M. L., Vasan, S., Tovanabutra, S., & Ananworanich, J. (2020). Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. Open forum infectious diseases, 7(10), ofaa429. https://doi.org/10.1093/ofid/ofaa429
Song, Hongshuo, et al. "Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection." Open forum infectious diseases vol. 7,10 (2020): ofaa429. doi: https://doi.org/10.1093/ofid/ofaa429
Song H, Bose M, Pinyakorn S, Sanders-Buell E, O'Sullivan AM, Silas D, Trichavaroj R, Nuntapinit B, Pham PT, Akapirat S, Kroon E, de Souza M, Gramzinski R, Michael NL, Robb ML, Vasan S, Tovanabutra S, Ananworanich J. Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa429. doi: 10.1093/ofid/ofaa429. eCollection 2020 Oct. PMID: 33748316; PMCID: PMC7958800.
Copy Download .nbib Format: NLM
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers.

Gut

Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, Walker R, Hutchinson RA, Preston S, Como J, Joseland S, Win AK, Macrae FA, Hopper JL, Mouradov D, Gibbs P, Sieber OM, O'Sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Winship IM, Buchanan DD.
PMID: 33414168
Gut. 2021 Nov;70(11):2138-2149. doi: 10.1136/gutjnl-2019-320462. Epub 2021 Jan 07.

OBJECTIVE: Germline pathogenic variants (PVs) in the DNA mismatch repair (MMR) genes and in the base excision repair gene DESIGN: Whole-exome sequencing of formalin-fixed paraffin-embedded (FFPE) CRC tissue was performed on 33 MMR germline PV carriers, 12 biallelic RESULTS:...

Cite
Georgeson P, Pope BJ, Rosty C, et al. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut. 2021;70(11):2138-2149doi: 10.1136/gutjnl-2019-320462.
Georgeson, P., Pope, B. J., Rosty, C., Clendenning, M., Mahmood, K., Joo, J. E., Walker, R., Hutchinson, R. A., Preston, S., Como, J., Joseland, S., Win, A. K., Macrae, F. A., Hopper, J. L., Mouradov, D., Gibbs, P., Sieber, O. M., O'Sullivan, D. E., Brenner, D. R., Gallinger, S., Jenkins, M. A., Winship, I. M., & Buchanan, D. D. (2021). Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut, 70(11), 2138-2149. https://doi.org/10.1136/gutjnl-2019-320462
Georgeson, Peter, et al. "Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers." Gut vol. 70,11 (2021): 2138-2149. doi: https://doi.org/10.1136/gutjnl-2019-320462
Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, Walker R, Hutchinson RA, Preston S, Como J, Joseland S, Win AK, Macrae FA, Hopper JL, Mouradov D, Gibbs P, Sieber OM, O'Sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Winship IM, Buchanan DD. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut. 2021 Nov;70(11):2138-2149. doi: 10.1136/gutjnl-2019-320462. Epub 2021 Jan 07. PMID: 33414168; PMCID: PMC8260632.
Copy Download .nbib Format: NLM
Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics.

Neuropharmacology

Schlag AK, O'Sullivan SE, Zafar RR, Nutt DJ.
PMID: 33940011
Neuropharmacology. 2021 Jun 15;191:108586. doi: 10.1016/j.neuropharm.2021.108586. Epub 2021 May 01.

Knowledge about the therapeutic potential of medical cannabis has greatly improved over the past decade, with an ever-increasing range of developments in human clinical applications. A growing body of scientific evidence supports the use of medical cannabis products for...

Cite
Schlag AK, O'Sullivan SE, Zafar RR, et al. Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021;191:108586doi: 10.1016/j.neuropharm.2021.108586.
Schlag, A. K., O'Sullivan, S. E., Zafar, R. R., & Nutt, D. J. (2021). Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology, 191108586. https://doi.org/10.1016/j.neuropharm.2021.108586
Schlag, Anne Katrin, et al. "Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics." Neuropharmacology vol. 191 (2021): 108586. doi: https://doi.org/10.1016/j.neuropharm.2021.108586
Schlag AK, O'Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021 Jun 15;191:108586. doi: 10.1016/j.neuropharm.2021.108586. Epub 2021 May 01. PMID: 33940011.
Copy Download .nbib Format: NLM
Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers.

Molecular cancer therapeutics

Hagerty B, O'Sullivan TN, Zhang X, Collins NK, Custer Lawrence W, Bassel LL, Pate N, Xu J, Guerin TM, Kozlov S, Alewine C.
PMID: 34315768
Mol Cancer Ther. 2021 Oct;20(10):2082-2092. doi: 10.1158/1535-7163.MCT-21-0017. Epub 2021 Jul 26.

Antibody-based therapies designed for human use frequently fail to cross-react with the murine isoform of their target. Because of this problem, preclinical studies of antibody-based mesothelin (Msl)-targeted therapeutics in immunocompetent systems have been limited by the lack of suitable...

Cite
Hagerty B, O'Sullivan TN, Zhang X, et al. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Mol Cancer Ther. 2021;20(10):2082-2092doi: 10.1158/1535-7163.MCT-21-0017.
Hagerty, B., O'Sullivan, T. N., Zhang, X., Collins, N. K., Custer Lawrence, W., Bassel, L. L., Pate, N., Xu, J., Guerin, T. M., Kozlov, S., & Alewine, C. (2021). Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular cancer therapeutics, 20(10), 2082-2092. https://doi.org/10.1158/1535-7163.MCT-21-0017
Hagerty, Brendan, et al. "Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers." Molecular cancer therapeutics vol. 20,10 (2021): 2082-2092. doi: https://doi.org/10.1158/1535-7163.MCT-21-0017
Hagerty B, O'Sullivan TN, Zhang X, Collins NK, Custer Lawrence W, Bassel LL, Pate N, Xu J, Guerin TM, Kozlov S, Alewine C. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Mol Cancer Ther. 2021 Oct;20(10):2082-2092. doi: 10.1158/1535-7163.MCT-21-0017. Epub 2021 Jul 26. PMID: 34315768; PMCID: PMC8492545.
Copy Download .nbib Format: NLM
Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study.

Journal of pharmaceutical and biomedical analysis

Reeder JA, Abdallah IA, Bach T, O'Sullivan CT, Xu Y, Nalbant D, An G.
PMID: 34979494
J Pharm Biomed Anal. 2021 Dec 06;210:114521. doi: 10.1016/j.jpba.2021.114521. Epub 2021 Dec 06.

Cefazolin is widely used during surgery to prevent surgical site infections (SSIs). Although cefazolin redosing is often needed due to its short half-life, the appropriate redosing schedule remains controversial and there is limited information on cefazolin disposition following repeated...

Cite
Reeder JA, Abdallah IA, Bach T, et al. Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2021;210:114521doi: 10.1016/j.jpba.2021.114521.
Reeder, J. A., Abdallah, I. A., Bach, T., O'Sullivan, C. T., Xu, Y., Nalbant, D., & An, G. (2021). Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 210114521. https://doi.org/10.1016/j.jpba.2021.114521
Reeder, Joshua A, et al. "Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study." Journal of pharmaceutical and biomedical analysis vol. 210 (2021): 114521. doi: https://doi.org/10.1016/j.jpba.2021.114521
Reeder JA, Abdallah IA, Bach T, O'Sullivan CT, Xu Y, Nalbant D, An G. Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2021 Dec 06;210:114521. doi: 10.1016/j.jpba.2021.114521. Epub 2021 Dec 06. PMID: 34979494.
Copy Download .nbib Format: NLM
Showing 313 to 324 of 324 entries